|
Characteristics
|
Total patients
|
Nav1.5 low expression
|
Nav1.5 high expression
|
P value
|
|---|
|
Clinical parameter
|
|
Gender
| | | |
0.384
|
|
Male
|
145 (53.9)
|
18 (12.4)
|
127 (87.6)
| |
|
Female
|
124 (46.1)
|
20 (16.1)
|
104 (83.9)
| |
|
Age (years)
|
|
≤ 60
|
136 (50.6)
|
21 (15.4)
|
115 (84.6)
|
0.532
|
|
> 60
|
133 (49.4)
|
17 (12.8)
|
116 (87.2)
| |
|
Tumor localization
| | | |
0.503
|
|
Right-sided colon
|
98 (36.4)
|
12 (12.2)
|
86 (87.8)
| |
|
Left-sided colon
|
171 (63.6)
|
26 (15.2)
|
145 (84.8)
| |
|
Preoperative serum CEA (ng/mL)a
| | | |
0.011
|
|
≤ 5
|
154 (62.6)
|
29 (18.8)
|
125 (81.2)
| |
|
> 5
|
92 (37.4)
|
6 (6.5)
|
86 (93.5)
| |
|
Preoperative serum CA199 (U/mL)b
| | | |
0.947
|
|
≤ 35
|
180 (81.1)
|
25 (13.9)
|
155 (86.1)
| |
|
> 35
|
42 (18.9)
|
6 (14.3)
|
36 (85.7)
| |
|
Adjuvant chemotherapy
| | | |
0.556
|
|
Yes
|
228 (84.8)
|
31 (81.6)
|
197 (85.3)
| |
|
No
|
41 (15.2)
|
7 (18.4)
|
34 (14.7)
| |
|
Pathologic feature
|
|
Tumor size (cm)
| | | |
0.863
|
|
≤ 5
|
138 (51.3)
|
19 (13.8)
|
119 (86.2)
| |
|
> 5
|
131 (48.7)
|
19 (14.5)
|
112 (85.5)
| |
|
Tumor differentiation
| | | |
0.983
|
|
Well and moderate
|
248 (92.2)
|
35 (14.1)
|
213 (85.9)
| |
|
Poor
|
21 (7.8)
|
3 (14.3)
|
18 (85.7)
| |
|
T category
| | | |
0.385
|
|
T1
|
17 (6.3)
|
8 (47.1)
|
9 (52.9)
| |
|
T2
|
50 (18.6)
|
4 (8.0)
|
46 (92.0)
| |
|
T3
|
108 (40.1)
|
9 (8.3)
|
99 (91.7)
| |
|
T4
|
94 (34.9)
|
17 (18.1)
|
77 (81.9)
| |
|
N category
| | | |
0.545
|
|
N0
|
195 (72.5)
|
26 (13.3)
|
169 (86.7)
| |
|
N1-2
|
74 (27.5)
|
12 (16.2)
|
62 (83.8)
| |
|
TNM stage
| | | |
0.836
|
|
I
|
61 (22.7)
|
11 (18.0)
|
50 (82.0)
| |
|
II
|
134 (49.8)
|
15 (11.2)
|
119 (88.8)
| |
|
III
|
74 (27.5)
|
12 (16.2)
|
62 (83.8)
| |
|
ER-β statusc
| | | |
0.024
|
|
Low expression
|
51 (19.8)
|
12 (23.5)
|
39 (76.5)
| |
|
High expression
|
206 (80.2)
|
23 (11.2)
|
183 (88.8)
| |
- All data are presented as number of patients followed by percentage in the parentheses
-
ER-β estrogen receptor-β, TNM tumor-node-metastasis, CEA carcinoembryonic antigen, CA199 cancer antigen (CA) 199
-
aThe data of preoperative CEA level were available in 246 patients
-
bThe data of preoperative CA199 level were available in 222 patients
-
cER-β status was evaluated in 257 patients
